In a new paper appearing in the Journal of Investigative Dermatology, a leading scientific publication in the field of research on skin and connective tissue, The Hormel Institute, University of ...

A 64-year-old woman presented to an outside provider with 5 days of left eye “burning, itching, redness and blurry vision” and 1 day of acute “9 out of 10” left eye pain.She had a medical history of ...

Corneal endothelium cell provides vital clinical information regarding the health status of the cornea, which is crucial to monitor different corneal diseases. In this regard, segmentation of the ...

If you have had a similar reaction to Pfizer's COVID-19 vaccine, email [email protected] with your storyScientists ...

Krystal Biotech announced the first patient has been dosed in EMERALD-1, its phase 1/2 clinical trial evaluating KB801 for ...

KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline ...

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

a human mesenchymal stem cell secretome (MCS-S), for the treatment of persistent corneal epithelial defect (PCED). The CHASE Phase 2b trial is a multicenter, randomized, double-masked, ...

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), ...

rapid protein clearance rates and high cell turnover in the front of the eye have severely limited the therapeutic potential of biologics and gene therapies for the treatment of corneal epithelial ...